Is IFRX or IMNM more undervalued in 2026?

CirclFi compares InflaRx N.V. (IFRX) and Immunome, Inc. (IMNM) using 13 institutional-grade valuation models. IFRX has a Quality of Company score of 1.8/10 while IMNM scores 5.0/10.

Which is a better buy — IFRX or IMNM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IFRX and IMNM valuations compare?

IFRX at $2.40 and IMNM at $21.83 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IFRX vs IMNM Valuation Comparison 2026 — Intrinsic Value Analysis

IFRX

Pharmaceutical Preparations

InflaRx N.V.

Quality

1.8

out of 10

Value Trap

—

Price

$2.40

Last close

Models

7/13

Active

IMNM

Pharmaceutical Preparations

Immunome, Inc.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$21.83

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	IFRX Fair Value	IFRX Upside	IMNM Fair Value	IMNM Upside
Bayesian DCF	Intrinsic	$0.64	-73.3%	$5.13	-76.5%
Earnings Power Value	Intrinsic	—	—	$3.35	-85.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$0.89	-63.0%	$20.90	-4.3%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IFRX vs IMNM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IFRX vs IMNM — Which Stock Is More Undervalued?

IMNM scores higher with a 5.0/10 quality rating vs IFRX's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing InflaRx N.V. (IFRX) and Immunome, Inc. (IMNM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IFRX currently trades at $2.40 with a QOC of 1.8/10, while IMNM trades at $21.83 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).